COVID-19: WHO recommends antiviral drug, molnupiravir for non-severe patients
The World Health Organisation (WHO), has conditionally recommended the antiviral drug molnupiravir, for patients with non-severe COVID-19 infection, who are at the highest risk of hospitalisation.
This was disclosed in a statement issued by the WHO Guideline Development Group of international experts according to the British Medical Journal on Thursday.
The recommendation, it said was for patients who are at the highest risk of hospitalisation typically including those who are unvaccinated, older people, and those with weak immune systems or chronic diseases.
In the statement, the WHO panel says that young and healthy patients, including children, and pregnant and breastfeeding women should not be given the drug due to potential harm.
“Molnupiravir is an antiviral medicine that works by stopping coronavirus from growing and spreading. Used as early as possible after infection, it can help prevent more severe symptoms from developing.”
“Today’s recommendation is based on new data from six randomised controlled trials involving 4,796 patients.
”This is the largest dataset on this drug so far,” it said.
It said that moderate certainty evidence from these trials suggests that molnupiravir reduces the risk of hospital admission (43 fewer admissions per 1,000 patients at highest risk) and time to symptom resolution (average 3.4 fewer days).
While low certainty evidence suggests a small effect on mortality (6 fewer deaths per 1,000 patients).
According to the statement, the panel describes mitigation strategies needed at the population level, including pharmacovigilance and antiviral resistance monitoring, given concerns about genotoxicity (damage to a cell’s genetic information causing mutations), the emergence of resistance, and new variants.
It said that the panel made no recommendation for patients with a severe or critical illness as there are no trial data on molnupiravir for this population.
The panel acknowledged that cost and availability issues associated with molnupiravir may make access to low and middle-income countries challenging and exacerbate health inequity.
Also, the guideline update said that the panel recommended a treatment combining two antibodies (casirivimab and imdevimab) to be used in people who are confirmed not to have the omicron variant.
It said that new evidence demonstrated a lack of effectiveness against the omicron variant.
“Today’s recommendations are part of a living guideline, developed by the WHO with the methodological support of MAGIC Evidence Ecosystem Foundation.
“This is to provide trustworthy guidance on the management of covid-19 and help doctors make better decisions with their patients,” it said.
It said that living guidelines are useful in fast-moving research areas like COVID-19 because they allow researchers to update previously vetted and peer-reviewed evidence summaries as new information become available.
“Today’s guidance adds to previous recommendations for the use of Baricitinib, interleukin-6 receptor blockers and systemic corticosteroids for patients with severe or critical COVID-19.”
“Also for the use of sotrovimab for patients with non-severe covid-19 and against the use of convalescent plasma, ivermectin and hydroxychloroquine in patients with covid-19 regardless of disease severity,” it said.
It said that the recommendation for remdesivir is undergoing review due to new trial data.
“Recommendations for fluvoxamine and nirmatrelvir/ritonavir are currently in preparation,” WHO said.
PHW
